Given the increasing discovery of oncogenic-driven tumours, targeted treatments with novel agents have transformed the outcomes in these patients. Clinical decision making and management therefore have become more complex. There is a need to provide an opportunity for medical oncologists, radiation oncologists, pathologists, allied health professionals, oncology nurses and pharmacists to engage in thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders.

Upon completion of this symposium, participants should be better able to:

• Summarise the evolving therapeutic strategies in the treatment of solid tumour malignancies.
• Provide an update of new molecular and targeted treatments being developed for these diseases.
• Discuss the rationale for new targeted diagnostic and therapeutic strategies for lung cancer, breast cancer, gastrointestinal tumours, genitourinary tumours, head and neck tumours, melanoma, sarcomas and brain tumours.
• Review the role and timing of diagnostic tests, molecular profiling and potential combinations of targeted therapy treatment options.